Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Pulmonary Arterial Hypertension
Interventions: Imatinib, Sildenafil, Bosentan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Tampa, Florida • Weston, Florida • Mineola, New York

Conditions: Drug-drug Interaction Study
Interventions: BMS-986020, Montelukast, Flurbiprofen, Digoxin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Gout, Food-drug Interaction
Interventions: ABP-671; Drug
Lead sponsor: Atom Therapeutics Co., Ltd; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Opioid Use Disorder
Interventions: Drug Cue, Money, Withdrawal, Remifentanil; Behavioral · Drug
Lead sponsor: Joshua A. Lile, Ph.D.; Other
Eligibility: 18 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Opioid Use Disorder
Interventions: Mobile Phone App; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Indianapolis, Indiana • Providence, Rhode Island

Conditions: Healthy, Enteric Hyperoxaluria
Interventions: FB-001, Placebo; Biological
Lead sponsor: Federation Bio Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections
Interventions: Abacavir sulfate, Amprenavir, Lamivudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068, Oral Contraceptive, Loestrin 1.5/30; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Miami, Florida • San Antonio, Texas

Conditions: Acute Kidney Injury, Adverse Drug Event
Interventions: Melatonin, Placebo Capsule; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Somerville, New Jersey

Conditions: Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma
Interventions: Durvalumab, Tremelimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Solid Tumors, Excluding Breast Cancer
Interventions: dovitinib (TKI258), fluvoxamine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: The Bronx, New York • San Antonio, Texas

Conditions: Obesity, Cardiovascular Diseases
Interventions: Naltrexone HCl/Bupropion HCl ER, Placebo; Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 139
States / cities: Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more

Conditions: Healthy Volunteers
Interventions: TAK-788, Placebo; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 15
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Hepatitis C, Medication Adherence
Interventions: Intensive Models (mDOT and CGT) of HCV Care; Other
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: HIV Infections
Interventions: tenofovir/BI 201335; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: HIV Infections
Interventions: Calanolide A; Drug
Lead sponsor: Sarawak MediChem Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 7
States / cities: Miami, Florida • Chicago, Illinois • Philadelphia, Pennsylvania + 3 more

Conditions: Asthma
Interventions: ASHMI 4, ASHMI 12, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Participants
Interventions: BMS-986165, Metformin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Obstructive Sleep Apnea
Interventions: Grass S88 Muscle Stimulator; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Nashvile, Tennessee

Conditions: Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injury, Central Nervous System Diseases, Spinal Cord Diseases, Gonadal Disorders, Endocrine System Diseases, Hypogonadism, Genital Diseases, Male, Spinal Cord Trauma, Injuries, Spinal Cord, Walking, Difficulty, Gait Disorders, Neurologic, Locomotion Disorder, Neurologic, Wounds and Injuries, Nervous System Diseases, Testosterone Deficiency, Androgen Deficiency, Hormone Deficiency
Interventions: Testosterone Enanthate, Locomotor Training; Drug · Behavioral
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Healthy Volunteers
Interventions: CT1812, tolbutamide, dextromethorphan, Omeprazole, midazolam; Drug
Lead sponsor: Cognition Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
Interventions: mRNA COVID-19, IIV4, Placebo (saline); Biological · Other
Lead sponsor: Duke University; Other
Eligibility: 5 Years and older
Enrollment: 348 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio

Conditions: Attention Deficit Hyperactivity Disorder, Problem Behavior
Interventions: Stimulant; Drug
Lead sponsor: Matthew J O'Brien, PhD, BCBA-D; Other
Eligibility: 48 Months to 12 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Iowa City, Iowa

Search by objective public record fields.

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

A Phase 1 Drug-drug Interaction Study in Healthy Volunteers

Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects

Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice

Mobile Peer Support for OUD Recovery

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

Melatonin for Prevention of Kidney Injury

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.

Naltrexone/Bupropion Cardiovascular Outcomes Study

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy Participants

The Effect of Anti-HIV Therapy on Fat Metabolism in HIV-Positive Patients

Intensive Models of HCV Care for Injection Drug Users

Drug Drug Interaction of BI 201335 and Tenofovir

The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Effectiveness of Chinese Herbal Therapy for Asthma

Effect of BMS-986165 on the Blood Levels of Metformin

Muscle Stimulation During DISE

Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury

Drug Interaction Study of CT1812 in Healthy Volunteers

Simultaneous mRNA COVID-19 and IIV4 Vaccination Study

Stimulant Effects on Disruptive Behavior